1）Ziesenitz VC, Vaughns JD, Koch G, Mikus G, van den Anker JN. Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. Clin Pharmacokinet 2018; 57: 125-49. 3）Fentanyl citrate [package insert]. Pfizer Inc. 4）Rasool MF, Ali S, Khalid S, Khalid R, Majeed A, Imran I, et al. Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases. Sci Rep 2021; 11: 8589. 5）Bellanti F, Della Pasqua O. Modelling and simulation as research tools in paediatric drug development. Eur J Clin Pharmacol 2011; 67 Suppl 1: 75-86. 6）Bista SR, Haywood A, Hardy J, Lobb M, Tapuni A, Norris R. Protein binding of fentanyl and its metabolite nor-fentanyl in human plasma, albumin and α-1 acid glycoprotein. Xenobiotica 2015; 45: 207-12. 7）Li H, Lampe JN. Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism. Arch Biochem Biophys 2019; 673: 108078. 8）Wojtyniak JG, Britz H, Selzer D, Schwab M, Lehr T. Data digitizing: accurate and precise data extraction for quantitative systems pharmacology and physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol 2020; 9: 322–31. 9）Koehntop DE, Rodman JH, Brundage DM, Hegland MG, Buckley JJ. Pharmacokinetics of fentanyl in neonates. Anesth Analg 1986; 65: 227-32.10）Saarenmaa E, Neuvonen PJ, Fellman V. Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. J Pediatr 2000; 136: 767-70. 2）Hughes CG, McGrane S, Pandharipande PP. Sedation in the intensive care setting. Clin Pharmacol 2012; 4: 53-63.（最終アクセス日：2024年10月30日）新生児におけるフェンタニルの有害反応と薬物動態の評価：生理学的薬物動態モデリング＆シミュレーションによるアプローチ文 献11）Singleton MA, Rosen JI, Fisher DM. Plasma concentrations of fentanyl in infants, children and adults. Can J Anaesth 1987; 34: 152-5.12）Gruber EM, Laussen PC, Casta A, Zimmerman AA, Zurakowski D, Reid R, et al. Stress response in infants undergoing cardiac surgery: a randomized study of fentanyl bolus, fentanyl infusion, and fentanyl-midazolam infusion. Anesth Analg 2001; 92: 882-90.13）Gauntlett IS, Fisher DM, Hertzka RE, Kuhls E, Spellman MJ, Rudolph C. Pharmacokinetics of fentanyl in neonatal humans and lambs: effects of age. Anesthesiology 1988; 69: 683-7.14）Norman E, Kindblom JM, Rane A, Berg AC, Schubert U, Hallberg B, et al. Individual variations in fentanyl pharmacokinetics and pharmacodynamics in preterm infants. Acta Paediatr 2019; 108: 1441-6.15）Roth B, Schlünder C, Houben F, Günther M, Theisohn M. Analgesia and sedation in neonatal intensive care using fentanyl by continuous infusion. Dev Pharmacol Ther 1991; 17: 121-7.16）Collins C, Koren G, Crean P, Klein J, Roy WL, MacLeod SM. Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. Anesth Analg 1985; 64: 1078-80.17）Schulz M, Schmoldt A, Andresen-Streichert H, Iwersen-Bergmann S. Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care 2020; 24: 195.18）Ziesenitz VC, König SK, Mahlke NS, Skopp G, Haefeli WE, Mikus G. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. J Clin Pharmacol 2015; 55: 708-17.19）Li Y, Dong N, Qin YX, Dai HR, Hu YH, Zhao YT, et al. Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration-to-dose ratio. Epilepsia Open 2022; 7: 737-46.29
元のページ ../index.html#43